X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Photo: Wikimedia Commons

The jury deliberating in the first punitive damages trial over Johnson & Johnson subsidiary Janssen’s conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.

This premium content is locked for
New Jersey Law Journal subscribers only.

*May exclude premium content
Already have an account?
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to groupsales@alm.com to learn more.

Max Mitchell

Max Mitchell is a reporter with The Legal Intelligencer, focusing on litigation in Pennsylvania with a specific emphasis on Philadelphia courts. Follow him on Twitter @MMitchellTLI.

More from this author

Law Firms Mentioned

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.